We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vaso Stock Slips Post Q1 Earnings Despite Record Revenue Growth
Read MoreHide Full Article
Shares of Vaso Corporation (VASO - Free Report) have declined 5.6% since the company reported its earnings for the quarter ended March 31, 2025, underperforming the S&P 500 Index’s 1.1% gain over the same time frame. Despite this short-term setback, the stock has risen 3.9% over the past month but still lagged behind the S&P 500’s impressive 15.4% growth.
VASO’s Revenue & Earnings Snapshot
For the first quarter of 2025, Vaso posted a 3.9% year-over-year increase in revenues to $19.5 million from $18.7 million in the prior-year quarter. The gross profit rose in tandem, increasing 4% to $11.4 million from $10.9 million in the prior-year quarter. Net loss for the quarter narrowed to $1.1 million from $1.2 million in the same period last year. Loss per share for the three months ended March 31, 2025 was $0.01, unchanged from the loss of $0.01 reported for the same period in 2024.
Segment-wise, revenues from professional sales services increased 7.1% to $8.7 million from $8.1 million in the prior-year quarter, largely driven by higher product deliveries from its partner. The IT segment grew 1.6% to $10.3 million from $10.2 million due to stronger network services sales, while the equipment segment saw a 3.5% decline to $0.4 million from $0.5 million, primarily owing to softer sales in China, which were partially offset by higher ARCS software subscription revenues in the United States.
Vaso: Operational Metrics and Efficiency Indicators
Vaso’s adjusted EBITDA remained negative but improved year over year to a loss of $1.1 million from a $1.3 million deficit in the prior-year quarter. This improvement aligns with the narrower net loss and suggests marginal progress toward operating efficiency.
The operating loss also improved, totaling $1.2 million compared with $1.5 million in the first quarter of 2024. Selling, general and administrative expenses rose 2.8% to $12.4 million from $12.1 million, reflecting increased personnel costs in the IT and sales segments, though these were partially offset by reductions in the equipment and corporate expense lines.
Vaso Corporation Price, Consensus and EPS Surprise
President and CEO Dr. Jun Ma characterized the quarter as a strong start to the year, noting that the $19.5 million in quarterly revenues marked a record first quarter for VASO. Dr. Ma highlighted the strength of the company’s balance sheet, citing $25.3 million in cash and cash equivalents as of March 31, 2025. He pointed to growth in deferred revenues — up 12.7% year over year to $35.4 million from $31.4 million in the prior-year quarter — as a signal of healthy future revenue streams. He added that historical patterns of stronger performance in later quarters and current backlog levels provide cause for cautious optimism in a generally uncertain business environment.
Revenue Drivers and Segment Performance of VASO
The professional sales service segment was the primary revenue driver in the quarter, contributing most significantly to the year-over-year revenue gain. The uptick in this segment stemmed from increased product deliveries by GE HealthCare, Vaso’s exclusive partner in diagnostic imaging and ultrasound sales within defined U.S. markets. In the IT segment, higher network service revenues offset a decline in healthcare IT sales, reflecting VASO’s continuing pivot toward more stable and scalable service offerings.
Meanwhile, the equipment segment experienced a modest revenue contraction due to reduced deliveries in Vaso’s China operations. However, this was mitigated by increased software subscription sales in the United States, hinting at a potential shift toward more recurring revenue models within that unit.
Cash flow from operations improved notably, with net cash used in operating activities totaling $566,000 in the quarter — better than the $1.1 million outflow in the prior-year period. As of May 9, 2025, Vaso’s cash reserves had increased to approximately $30.5 million, further supporting management’s assertions about financial strength.
Guidance Provided by Vaso
Vaso did not issue quantitative guidance for the full year but reiterated its belief in stronger profitability in the latter half of 2025. Management expressed confidence that deferred revenue levels and backlogs across IT and equipment divisions would translate into financial visibility and stability going forward. VASO acknowledged broader macroeconomic uncertainties but indicated that its diversified portfolio and balance sheet strength position it well to navigate near-term volatility.
Other Developments at VASO
No acquisitions, divestitures or restructuring initiatives were disclosed during the first quarter. Vaso’s operational structure remained unchanged, continuing to function through its three wholly owned subsidiaries: VasoTechnology, VasoHealthcare and VasoMedical. These units respectively manage IT and network services, sales partnerships with GE HealthCare, and proprietary medical device development and manufacturing, including the company’s China-based operations.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vaso Stock Slips Post Q1 Earnings Despite Record Revenue Growth
Shares of Vaso Corporation (VASO - Free Report) have declined 5.6% since the company reported its earnings for the quarter ended March 31, 2025, underperforming the S&P 500 Index’s 1.1% gain over the same time frame. Despite this short-term setback, the stock has risen 3.9% over the past month but still lagged behind the S&P 500’s impressive 15.4% growth.
VASO’s Revenue & Earnings Snapshot
For the first quarter of 2025, Vaso posted a 3.9% year-over-year increase in revenues to $19.5 million from $18.7 million in the prior-year quarter. The gross profit rose in tandem, increasing 4% to $11.4 million from $10.9 million in the prior-year quarter. Net loss for the quarter narrowed to $1.1 million from $1.2 million in the same period last year. Loss per share for the three months ended March 31, 2025 was $0.01, unchanged from the loss of $0.01 reported for the same period in 2024.
Segment-wise, revenues from professional sales services increased 7.1% to $8.7 million from $8.1 million in the prior-year quarter, largely driven by higher product deliveries from its partner. The IT segment grew 1.6% to $10.3 million from $10.2 million due to stronger network services sales, while the equipment segment saw a 3.5% decline to $0.4 million from $0.5 million, primarily owing to softer sales in China, which were partially offset by higher ARCS software subscription revenues in the United States.
Vaso: Operational Metrics and Efficiency Indicators
Vaso’s adjusted EBITDA remained negative but improved year over year to a loss of $1.1 million from a $1.3 million deficit in the prior-year quarter. This improvement aligns with the narrower net loss and suggests marginal progress toward operating efficiency.
The operating loss also improved, totaling $1.2 million compared with $1.5 million in the first quarter of 2024. Selling, general and administrative expenses rose 2.8% to $12.4 million from $12.1 million, reflecting increased personnel costs in the IT and sales segments, though these were partially offset by reductions in the equipment and corporate expense lines.
Vaso Corporation Price, Consensus and EPS Surprise
Vaso Corporation price-consensus-eps-surprise-chart | Vaso Corporation Quote
Management Commentary
President and CEO Dr. Jun Ma characterized the quarter as a strong start to the year, noting that the $19.5 million in quarterly revenues marked a record first quarter for VASO. Dr. Ma highlighted the strength of the company’s balance sheet, citing $25.3 million in cash and cash equivalents as of March 31, 2025. He pointed to growth in deferred revenues — up 12.7% year over year to $35.4 million from $31.4 million in the prior-year quarter — as a signal of healthy future revenue streams. He added that historical patterns of stronger performance in later quarters and current backlog levels provide cause for cautious optimism in a generally uncertain business environment.
Revenue Drivers and Segment Performance of VASO
The professional sales service segment was the primary revenue driver in the quarter, contributing most significantly to the year-over-year revenue gain. The uptick in this segment stemmed from increased product deliveries by GE HealthCare, Vaso’s exclusive partner in diagnostic imaging and ultrasound sales within defined U.S. markets. In the IT segment, higher network service revenues offset a decline in healthcare IT sales, reflecting VASO’s continuing pivot toward more stable and scalable service offerings.
Meanwhile, the equipment segment experienced a modest revenue contraction due to reduced deliveries in Vaso’s China operations. However, this was mitigated by increased software subscription sales in the United States, hinting at a potential shift toward more recurring revenue models within that unit.
Cash flow from operations improved notably, with net cash used in operating activities totaling $566,000 in the quarter — better than the $1.1 million outflow in the prior-year period. As of May 9, 2025, Vaso’s cash reserves had increased to approximately $30.5 million, further supporting management’s assertions about financial strength.
Guidance Provided by Vaso
Vaso did not issue quantitative guidance for the full year but reiterated its belief in stronger profitability in the latter half of 2025. Management expressed confidence that deferred revenue levels and backlogs across IT and equipment divisions would translate into financial visibility and stability going forward. VASO acknowledged broader macroeconomic uncertainties but indicated that its diversified portfolio and balance sheet strength position it well to navigate near-term volatility.
Other Developments at VASO
No acquisitions, divestitures or restructuring initiatives were disclosed during the first quarter. Vaso’s operational structure remained unchanged, continuing to function through its three wholly owned subsidiaries: VasoTechnology, VasoHealthcare and VasoMedical. These units respectively manage IT and network services, sales partnerships with GE HealthCare, and proprietary medical device development and manufacturing, including the company’s China-based operations.